Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First-Ever Stem Cell GMP Warning Letter Cites IntelliCell

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA finds the company failed to establish procedures for a range of GMP basics, which is a problem because according to the agency the IntelliCell adipose tissue-derived stem cells are both a drug and a biologic product.

You may also be interested in...



Celltex’s Stem Cell Manufacturing To Be Regulated As A Biological Drug

FDA tells Celltex Therapeutics that its stem cell treatments are to be regulated as biologics; company contends they should be considered a human cell and tissue product.

Baxter Alerted FDA To Problem Before Receiving Warning Letter, Firm Says

The letter details problems related to Baxter's use of albumin in the manufacturing of its Isolex 300i Magnetic Cell Selection System, a device/biologic regulated as a Class III device.

Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?

Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel